Small molecule · Inhibitor of influenza virus neuraminidase · developed by Biocryst
Peramivir is a cyclopentane derivative that inhibits the influenza virus neuraminidase, preventing release of new virus particles from infected cells.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 18, 2024). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01224795 | Phase 3 | Influenza | Withdrawn | BCRX |
| NCT00958776 | Phase 3 | Cough | Terminated | BCRX |
| NCT00486980 | Phase 3 | Influenza | Withdrawn | BCRX |
| NCT00453999 | Phase 2 | Influenza | Completed | BCRX |
| NCT00419263 | Phase 2 | Influenza | Completed | BCRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CoughFeverHeadacheInfluenzaNasal CongestionSeasonal InfluenzaSore Throat
Updated Oct 11, 2026. Something wrong or missing? Report it on the BCRX page.
See BCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BCRX catalysts and pipeline →